Aytu (AYTU) Q3 2026 Earnings Transcript

Aytu BioPharma reported Q3 net revenue of $12.4 million, with EXXUA contributing $2.4 million in its first meaningful commercial quarter despite only partial sales-force deployment. EXXUA prescriptions exceeded 1,300 for the quarter, unique prescribers topped 450, and April prescriptions rose to more than 920, signaling accelerating early launch traction. Offsetting this, legacy ADHD and pediatric revenue declined year over year, and the company posted a $5.6 million net loss, but balance sheet strength improved after a warrant amendment lifted stockholders’ equity to $35.1 million.

Analysis

The market is likely underestimating how quickly EXXUA can re-rate AYTU’s business mix because this is less a one-quarter revenue event than the start of a self-reinforcing access loop. Early refill behavior, broad geographic reach beyond the rep footprint, and >70% first-pass approval inside the controlled channel suggest the launch is already doing the hardest part: converting physician curiosity into habitual prescribing. The more important second-order effect is that stocking revenue front-loads P&L before the true refill engine is visible, so headline sales can understate the durability of demand while gross-to-net temporarily obscures operating leverage.

The bear case is not demand; it is launch efficiency and balance-sheet absorption. Management is signaling another step-up in spend next quarter, so the question becomes whether incremental dollars convert into a widening prescriber base or merely maintain the current pace of channel fill. If the April prescription run-rate persists while stocking normalizes, the revenue mix should improve materially, but any stall in refills or payer friction would compress sentiment quickly because the stock is now trading on execution, not optionality.

The balance-sheet cleanup matters more than the company is framing it. Removing warrant-liability volatility lowers the probability that good operating news is masked by accounting noise, which can improve the quality of any future re-rating and reduce forced de-risking by event-driven holders. The contrarian risk is that investors focus on legacy revenue erosion and miss that the launch only needs modest monthly growth to offset it; conversely, if commercial insurance economics tighten after the initial access push, the current net-price optimism could prove transitory. This is a near-term data-driven story, not a multi-year thesis until refill persistence through month 3+ is validated.

Key Decisions for Investors

• Long AYTU into the next 4-8 weeks only on pullbacks, using a starter position sized for event risk; thesis is that the market is still discounting the refill/repurchase curve and the stock can re-rate on another month of sequential prescription growth.
• Buy AYTU calls or call spreads 1-3 months out if liquidity permits; best setup is a defined-risk upside trade into the next launch update, with the main catalyst being normalization of stocking and confirmation that April's run-rate is not a one-off.
• Pair trade: long AYTU / short a basket of small-cap pharma names with fading legacy products and no near-term launch catalyst; this isolates launch execution alpha from sector beta.
• Do not chase AYTU after sharp up days until the company reports refill persistence and gross-to-net stabilization; if the next update shows slower unit shipments without matching refill growth, trim quickly because the stock is likely pricing in too much stocking revenue already.
• Watch for a secondary financing window; if cash burn accelerates toward the high-spend guidance range before EXXUA turns cash generative, consider fading rallies or hedging long exposure with short-dated puts.